Orion Corporation is preparing to issue a EUR 100-150 million senior, unsecured bond that would mature in 5-7 years. Also, an application would be made to have the bond listed on NASDAQ OMX Helsinki. The proceeds from the bond offering would be used for general corporate purposes.
Orion Corporation has mandated Pohjola Bank to arrange domestic and international fixed income meetings commencing 22nd of May 2013. Bond issue may follow, subject to market conditions.
Orion Corporation
| Timo Lappalainen President and CEO | Jari Karlson CFO |
Contact person:
Jari Karlson, CFO
tel. +358 10 426 2883
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi
Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. Pharmaceutical R&D focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler® pulmonary drugs.
Orion's net sales in 2012 amounted to EUR 980 million and the company had about 3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.